voriconazole

Drug-drug:

Carbamazepine, phenobarbital, and rifampin may significantly ↓ levels and effectiveness; concurrent use contraindicated.
May significantly ↑ levels of ivabradine, pimozide, and quinidine, which can ↑ the risk of QT interval prolongation and torsades de pointes; concurrent use contraindicated.
May significantly ↑ levels and risk of toxicity of dihydroergotamine, ergotamine, lurasidone, sirolimus, and tolvaptan; concurrent use contraindicated.
May ↑ levels of naloxegol, which could precipitate symptoms of opioid withdrawal; concurrent use contraindicated.
Concurrent use with efavirenz at dose of ≥400 mg every 24 hr is contraindicated, as it may significantly ↑ efavirenz levels and significantly ↓ voriconazole levels; if used together, ↑ oral maintenance dose of voriconazole to 400 mg every 12 hr and ↓ dose of efavirenz to 300 mg daily.
Concurrent use with ritonavir at dose of 400 mg every 12 hr is contraindicated, as ritonavir may significantly ↓ voriconazole levels; use with ritonavir at dose of 100 mg every 12 hr; should be avoided if possible.
Concurrent use with rifabutin may significantly ↑ rifabutin levels and significantly ↓ voriconazole levels; concurrent use contraindicated; if used together, ↑ oral maintenance dose of voriconazole to 400 mg every 12 hr and ↓ dose of efavirenz to 300 mg daily.
Concurrent use with venetoclax at initiation and during ramp-up phase in patients with chronic lymphocytic leukemia or small lymphocytic leukemia is contraindicated because may ↑ risk of tumor lysis syndrome.
May significantly ↑ levels of finerenone, which could ↑ risk of hyperkalemia; concurrent use contraindicated.
Fluconazole may ↑ levels and risk of toxicity; avoid concurrent use.
May ↑ levels and risk of toxicity of cyclosporine; ↓ cyclosporine dose by 50%.
May ↑ levels and risk of toxicity of tacrolimus; ↓ tacrolimus dose to ⅓ of the starting dose.
May ↑ levels and risk of toxicity of glasdegib; avoid concurrent use.
May ↑ levels and risk of toxicity of tyrosine kinase inhibitors, including axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, ibrutinib, nilotinib, ribociclib, and sunitinib; if concurrent use cannot be avoided, ↓ tyrosine kinase inhibitor dose.
May ↑ levels and risk of toxicity of eszopiclone; ↓ eszopiclone dose.
May ↑ levels and risk of toxicity of tretinoin; closely monitor patient for signs/symptoms of pseudotumor cerebri or hypercalcemia.
May ↑ levels and risk of toxicity of HMG-CoA reductase inhibitors, some benzodiazepines (alprazolam, midazolam, triazolam), fentanyl, oxycodone, NSAIDs (ibuprofen, diclofenac), some calcium channel blockers, sulfonylureas (glipizide, glyburide), phenytoin, warfarin, and vinca alkaloids (vincristine, vinblastine); dose ↓ may be needed and careful monitoring required during concurrent use.
May ↑ methadone levels and risk of QT interval prolongation.
May ↑ levels of corticosteroids and risk of adrenal suppression.
May ↑ levels and risk of toxicity of ivacaftor; ↓ ivacaftor dose.
Concurrent use with hormonal contraceptives containing ethinyl estradiol and norethindrone may ↑ voriconazole, ethinyl estradiol, and norethindrone levels.
May ↑ levels and risk of toxicity of everolimus; concurrent use not recommended.
May ↑ levels and risk of toxicity of omeprazole; if patient receiving ≥40 mg/day of omeprazole, ↓ omeprazole dose by 50%. Similar effects may occur with other proton pump inhibitors.
May ↑ levels and risk of toxicity of protease inhibitors and non-nucleoside reverse transcriptase inhibitors; frequent monitoring recommended.
Non-nucleoside reverse transcriptase inhibitors may induce or inhibit the metabolism of voriconazole; frequent monitoring recommended.
Letermovir may ↓ levels and effectiveness; avoid concurrent use.
Use with methotrexate may ↑ risk of photosensitivity reactions.

Drug-Natural Products:

St. John's wort may significantly ↓ levels and effectiveness; concurrent use contraindicated.

Availability ⬆ ⬇

(Generic available)

Tablets: 50 mg; 200 mg
Oral suspension orange flavor: 40 mg/mL
Powder for injection: 200 mg/vial

Route/Dosage ⬆ ⬇

Invasive Aspergillosis, Scedosporiosis, or Fusariosis

IV PO (Adults ≥40 kg): Loading dose (IV): 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 4 mg/kg IV every 12 hr (use 5 mg/kg IV every 12 hr if concurrently using with phenytoin). Continue IV therapy for ≥7 days; then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 200 mg PO every 12 hr (use 400 mg PO every 12 hr if concurrently using with phenytoin or efavirenz); if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: ≥6–12 wk.
IV PO (Adults <40 kg): Loading dose (IV): 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 4 mg/kg IV every 12 hr (use 5 mg/kg IV every 12 hr if concurrently using with phenytoin). Continue IV therapy for ≥7 days; then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 100 mg PO every 12 hr (use 200 mg PO every 12 hr if concurrently using with phenytoin; use 400 mg PO every 12 hr if concurrently using with efavirenz); if response inadequate, may ↑ to 150 mg every 12 hr. Total duration of therapy: ≥6–12 wk.
IV PO (Children ≥15 yr): Loading dose (IV): 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 4 mg/kg IV every 12 hr. Continue IV therapy for ≥7 days; then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: ≥6–12 wk.
IV PO (Children 12–14 yr and ≥50 kg): Loading dose (IV): 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 4 mg/kg IV every 12 hr. Continue IV therapy for ≥7 days; then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: ≥6–12 wk.
IV PO (Children 12–14 yr and <50 kg): Loading dose (IV): 9 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 8 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Continue IV therapy for ≥7 days; then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: ≥6–12 wk.
IV PO (Children 2–11 yr): Loading dose (IV): 9 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 8 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Continue IV therapy for ≥7 days; then switch to oral maintenance dose once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: ≥6–12 wk.

Hepatic Impairment

IV PO (Adults ): Mild or moderate hepatic impairment: Use standard IV loading dose; ↓ maintenance doses (IV or PO) by 50%; Severe hepatic impairment: Not recommended.

Candidemia in Non-Neutropenic Patients or Other Deep Tissue Candida Infections

IV PO (Adults ≥40 kg): Loading dose (IV): 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 3–4 mg/kg IV every 12 hr (use 5 mg/kg IV every 12 hr if concurrently using with phenytoin). Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 200 mg PO every 12 hr (use 400 mg PO every 12 hr if concurrently using with phenytoin or efavirenz); if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: ≥14 days following resolution of symptoms or following last positive culture, whichever is longer.
IV PO (Adults <40 kg): Loading dose (IV): 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 3–4 mg/kg IV every 12 hr (use 5 mg/kg IV every 12 hr if concurrently using with phenytoin). Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 100 mg PO every 12 hr (use 200 mg PO every 12 hr if concurrently using with phenytoin; use 400 mg PO every 12 hr if using concurrently with efavirenz); if response inadequate, may ↑ to 150 mg every 12 hr. Total duration of therapy: ≥14 days following resolution of symptoms or following last positive culture, whichever is longer.
IV PO (Children ≥15 yr): Loading dose (IV): 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 3–4 mg/kg IV every 12 hr. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: ≥14 days following resolution of symptoms or following last positive culture, whichever is longer.
IV PO (Children 12–14 yr and ≥50 kg): Loading dose (IV): 6 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 3–4 mg/kg IV every 12 hr. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Total duration of therapy: ≥14 days following resolution of symptoms or following last positive culture, whichever is longer.
IV PO (Children 12–14 yr and <50 kg): Loading dose (IV): 9 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 8 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: ≥14 days following resolution of symptoms or following last positive culture, whichever is longer.
IV PO (Children 2–11 yr): Loading dose (IV): 9 mg/kg IV every 12 hr for 2 doses, followed by maintenance dose (IV) of 8 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: ≥14 days following resolution of symptoms or following last positive culture, whichever is longer.

Hepatic Impairment

IV PO (Adults ): Mild or moderate hepatic impairment: Use standard IV loading dose; ↓ maintenance doses (IV or PO) by 50%; Severe hepatic impairment: Not recommended.

Esophageal Candidiasis

PO (Adults ≥40 kg): 200 mg every 12 hr (use 400 mg every 12 hr if concurrently using with phenytoin or efavirenz); if response inadequate, may ↑ to 300 mg every 12 hr. Duration of therapy: ≥14 days and for ≥7 days following resolution of symptoms.
PO (Adults <40 kg): 100 mg every 12 hr (use 200 mg every 12 hr if concurrently using with phenytoin; use 400 mg every 12 hr if using concurrently with efavirenz); if response inadequate, may ↑ to 150 mg every 12 hr. Duration of therapy: ≥14 days and for ≥7 days following resolution of symptoms.
PO (Children ≥15 yr): 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Duration of therapy: ≥14 days and for ≥7 days following resolution of symptoms.
PO (Children 12–14 yr and ≥50 kg): 200 mg every 12 hr; if response inadequate, may ↑ to 300 mg every 12 hr. Duration of therapy: ≥14 days and for ≥7 days following resolution of symptoms.
IV PO (Children 12–14 yr and <50 kg): Initiate therapy with maintenance dose (IV) of 4 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: ≥14 days and for ≥7 days following resolution of symptoms.
IV PO (Children 2–11 yr): Initiate therapy with maintenance dose (IV) of 4 mg/kg IV every 12 hr; if response inadequate, may ↑ maintenance dose by 1 mg/kg. Switch to oral dosing once patient has clinically improved and can tolerate oral medications. Maintenance dose (PO): 9 mg/kg every 12 hr (not to exceed 350 mg every 12 hr); if response inadequate, may ↑ by 1 mg/kg or 50 mg (not to exceed 350 mg every 12 hr). Total duration of therapy: ≥14 days and for ≥7 days following resolution of symptoms.

Hepatic Impairment

IV PO (Adults ): Mild or moderate hepatic impairment: Use standard IV loading dose; ↓ maintenance doses (IV or PO) by 50%; Severe hepatic impairment: Not recommended.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Inhibits fungal ergosterol synthesis leading to production of abnormal fungal plasma membrane.

Therapeutic effects:

Antifungal activity.

Spectrum:

Spectrum is notable for activity against:
- Aspergillus spp.,
- Candida spp.,
- Scedosporium apiospermum,
- Fusarium spp.

Classifications ⬆ ⬇

Therapeutic Classification: antifungals

Pharmacologic Classification: azoles

Pharmacokinetics ⬆ ⬇

Absorption: 96% absorbed following oral administration; IV administration results in complete bioavailability.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Primarily metabolized by liver via the CYP2C19, CYP2C9, and CYP3A4 isoenzymes; <2% excreted unchanged in urine. The CYP2C19 isoenzyme exhibits genetic polymorphism; 15–20% of Asian patients and 3–5% of White and Black patients may be poor metabolizers and may have significantly ↑ voriconazole concentrations and an ↑ risk of adverse effects.

Half-Life: Dose-dependent (adults: 6–9 hr); ↑ in hepatic impairment.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	rapid	1–2 hr	12 hr
IV	rapid	end of infusion	12 hr

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy. Advise patient to take as directed, on an empty stomach.
Instruct patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care provider before taking any new medications.
May cause blurred vision, photophobia, and dizziness. Caution patient to avoid driving and other activities requiring alertness until response to medication is known. Also advise patient to avoid driving at night.
Advise patient to avoid direct sunlight, sunlamps, and tanning beds. Use sunscreen and protective clothing to prevent severe sunburn. Advise patient to have dermatologic evaluation on a regular basis to allow early detection and management of premalignant lesions; squamous cell carcinoma of the skin and melanoma have been reported during long-term therapy.
Advise patient to notify health care provider if rash or signs and symptoms of allergic reaction occur.
Rep: May cause fetal harm. Advise women of reproductive potential to use effective contraception and notify health care provider if pregnancy is planned or suspected or if breastfeeding. Monitor for adverse reactions if voriconazole is administered concurrently with oral contraceptives.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0049- Roerig
- 0049-3160- VFEND
  - 0049-3160-44- 1 BOTTLE in 1 CARTON (0049-3160-44) / 75 mL in 1 BOTTLE

0049- Roerig
- 0049-3170- VFEND
  - 0049-3170-30- 30 TABLET, FILM COATED in 1 BOTTLE (0049-3170-30)

0049- Roerig
- 0049-3180- VFEND
  - 0049-3180-30- 30 TABLET, FILM COATED in 1 BOTTLE (0049-3180-30)

0049- Roerig
- 0049-3190- VFEND
  - 0049-3190-01- 1 VIAL, SINGLE-USE in 1 CARTON (0049-3190-01) / 20 mL in 1 VIAL, SINGLE-USE

0049- Roerig
- 0049-3190- VFEND
  - 0049-3190-28- 1 VIAL, SINGLE-DOSE in 1 CARTON (0049-3190-28) / 20 mL in 1 VIAL, SINGLE-DOSE

0049- Roerig
- 0049-4190- VFEND
  - 0049-4190-01- 1 VIAL, SINGLE-USE in 1 CARTON (0049-4190-01) / 20 mL in 1 VIAL, SINGLE-USE

0378- Mylan Pharmaceuticals Inc.
- 0378-1626- Voriconazole
  - 0378-1626-93- 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-1626-93)

0378- Mylan Pharmaceuticals Inc.
- 0378-1640- Voriconazole
  - 0378-1640-93- 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-1640-93)

0781- Sandoz Inc
- 0781-3416- Voriconazole
  - 0781-3416-94- 1 VIAL, SINGLE-USE in 1 CARTON (0781-3416-94) / 20 mL in 1 VIAL, SINGLE-USE

0781- Sandoz Inc
- 0781-5667- voriconazole
  - 0781-5667-05- 500 TABLET, FILM COATED in 1 BOTTLE (0781-5667-05)

0781- Sandoz Inc
- 0781-5667- voriconazole
  - 0781-5667-10- 1000 TABLET, FILM COATED in 1 BOTTLE (0781-5667-10)

0781- Sandoz Inc
- 0781-5667- voriconazole
  - 0781-5667-13- 10 BLISTER PACK in 1 CARTON (0781-5667-13) / 10 TABLET, FILM COATED in 1 BLISTER PACK (0781-5667-06)

0781- Sandoz Inc
- 0781-5667- voriconazole
  - 0781-5667-31- 30 TABLET, FILM COATED in 1 BOTTLE (0781-5667-31)

0781- Sandoz Inc
- 0781-5668- voriconazole
  - 0781-5668-05- 500 TABLET, FILM COATED in 1 BOTTLE (0781-5668-05)

0781- Sandoz Inc
- 0781-5668- voriconazole
  - 0781-5668-10- 1000 TABLET, FILM COATED in 1 BOTTLE (0781-5668-10)

0781- Sandoz Inc
- 0781-5668- voriconazole
  - 0781-5668-13- 10 BLISTER PACK in 1 CARTON (0781-5668-13) / 10 TABLET, FILM COATED in 1 BLISTER PACK (0781-5668-06)

0781- Sandoz Inc
- 0781-5668- voriconazole
  - 0781-5668-31- 30 TABLET, FILM COATED in 1 BOTTLE (0781-5668-31)

0904- Major Pharmaceuticals
- 0904-6596- voriconazole
  - 0904-6596-04- 30 BLISTER PACK in 1 CARTON (0904-6596-04) / 1 TABLET in 1 BLISTER PACK

0904- Major Pharmaceuticals
- 0904-7024- Voriconazole
  - 0904-7024-04- 30 BLISTER PACK in 1 CARTON (0904-7024-04) / 1 TABLET in 1 BLISTER PACK

14335- Hainan Poly Pharm. Co., Ltd.
- 14335-450-
  - 14335-450-01- 20 kg in 1 DRUM (14335-450-01)

14501- MSN Laboratories Private Limited
- 14501-0014-
  - 14501-0014-2- 50 kg in 1 DRUM (14501-0014-2)

16714- NorthStar Rx LLC
- 16714-198- Voriconazole
  - 16714-198-01- 30 TABLET, FILM COATED in 1 BOTTLE (16714-198-01)

16714- NorthStar Rx LLC
- 16714-199- Voriconazole
  - 16714-199-01- 30 TABLET, FILM COATED in 1 BOTTLE (16714-199-01)

27241- Ajanta Pharma USA Inc.
- 27241-062- Voriconazole
  - 27241-062-03- 30 TABLET in 1 BOTTLE (27241-062-03)

27241- Ajanta Pharma USA Inc.
- 27241-063- Voriconazole
  - 27241-063-03- 30 TABLET in 1 BOTTLE (27241-063-03)

31722- Camber Pharmaceuticals, Inc.
- 31722-224- Voriconazole
  - 31722-224-31- 1 VIAL, SINGLE-DOSE in 1 CARTON (31722-224-31) / 20 mL in 1 VIAL, SINGLE-DOSE

31722- Camber Pharmaceuticals, Inc.
- 31722-266- Voriconazole
  - 31722-266-31- 1 BOTTLE in 1 CARTON (31722-266-31) / 75 mL in 1 BOTTLE

40032- Novel Laboratories, Inc.
- 40032-038- VORICONAZOLE
  - 40032-038-60- 1 BOTTLE in 1 CARTON (40032-038-60) / 75 mL in 1 BOTTLE (40032-038-00)

43386- Lupin Pharmaceuticals,Inc.
- 43386-038- VORICONAZOLE
  - 43386-038-60- 1 BOTTLE in 1 CARTON (43386-038-60) / 75 mL in 1 BOTTLE

43386- Lupin Pharmaceuticals,Inc.
- 43386-088- voriconazole
  - 43386-088-03- 30 TABLET, FILM COATED in 1 BOTTLE (43386-088-03)

43386- Lupin Pharmaceuticals,Inc.
- 43386-089- voriconazole
  - 43386-089-03- 30 TABLET, FILM COATED in 1 BOTTLE (43386-089-03)

43547- Solco Healthcare U.S., LLC
- 43547-377- Voriconazole
  - 43547-377-03- 30 TABLET, COATED in 1 BOTTLE (43547-377-03)

43547- Solco Healthcare U.S., LLC
- 43547-377- Voriconazole
  - 43547-377-50- 500 TABLET, COATED in 1 BOTTLE (43547-377-50)

43547- Solco Healthcare U.S., LLC
- 43547-378- Voriconazole
  - 43547-378-03- 30 TABLET, COATED in 1 BOTTLE (43547-378-03)

43547- Solco Healthcare U.S., LLC
- 43547-378- Voriconazole
  - 43547-378-50- 500 TABLET, COATED in 1 BOTTLE (43547-378-50)

50268- AvPAK
- 50268-803- Voriconazole
  - 50268-803-12- 20 BLISTER PACK in 1 BOX (50268-803-12) / 1 TABLET, COATED in 1 BLISTER PACK (50268-803-11)

51079- Mylan Institutional Inc.
- 51079-164- Voriconazole
  - 51079-164-03- 30 BLISTER PACK in 1 CARTON (51079-164-03) / 1 TABLET, FILM COATED in 1 BLISTER PACK (51079-164-01)

51079- Mylan Institutional Inc.
- 51079-165- Voriconazole
  - 51079-165-03- 30 BLISTER PACK in 1 CARTON (51079-165-03) / 1 TABLET, FILM COATED in 1 BLISTER PACK (51079-165-01)

51552- Fagron Inc
- 51552-1524-
  - 51552-1524-2- 5 g in 1 CONTAINER (51552-1524-2)

51552- Fagron Inc
- 51552-1524-
  51552-1524-3- 25 g in 1 CONTAINER (51552-1524-3)

51552- Fagron Inc
- 51552-1573-
  51552-1573-2- 5 g in 1 CONTAINER (51552-1573-2)

51552- Fagron Inc
- 51552-1573-
  51552-1573-5- 25 g in 1 CONTAINER (51552-1573-5)

51927- Professional Compounding Centers of America
- 51927-5286-
  51927-5286-0- 1 kg in 1 BOTTLE (51927-5286-0)

52562- Chromo Laboratories India Private Limited
- 52562-001-
  52562-001-01- 1 kg in 1 CONTAINER (52562-001-01)

53296- Medichem S.A.
- 53296-0081-
  53296-0081-0- 75 kg in 1 DRUM (53296-0081-0)

55111- Dr. Reddy's Laboratories Limited
- 55111-099-
  55111-099-00- 1 kg in 1 DRUM (55111-099-00)

55150- Eugia US LLC
- 55150-321- Voriconazole
  55150-321-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-321-01) / 20 mL in 1 VIAL, SINGLE-DOSE

58032- Neuland Laboratories Limited
- 58032-2007-
  - 58032-2007-0- 1 kg in 1 DRUM (58032-2007-0)

59762- Mylan Pharmaceuticals Inc.
- 59762-0935- Voriconazole
  59762-0935-3- 1 BOTTLE in 1 CARTON (59762-0935-3) / 75 mL in 1 BOTTLE

60687- American Health Packaging
- 60687-273- Voriconazole
  - 60687-273-21- 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-273-21) / 1 TABLET, FILM COATED in 1 BLISTER PACK (60687-273-11)

60687- American Health Packaging
- 60687-294- Voriconazole
  - 60687-294-21- 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-294-21) / 1 TABLET, FILM COATED in 1 BLISTER PACK (60687-294-11)

60715- Pfizer Ireland Pharmaceuticals Unlimited Company
- 60715-1700-
  - 60715-1700-1- 1 BAG in 1 DRUM (60715-1700-1) / 25 kg in 1 BAG

63126- Yung Shin Pharm. Ind. Co., Ltd.
- 63126-911-
  63126-911-01- 10 kg in 1 BAG (63126-911-01)

63552- Patheon Manufacturing Services LLC
- 63552-221-
  63552-221-00- 189 VIAL in 1 CASE (63552-221-00) / 30 mL in 1 VIAL

63629- Bryant Ranch Prepack
- 63629-8734- voriconazole
  63629-8734-1- 30 TABLET, FILM COATED in 1 BOTTLE (63629-8734-1)

63739- Mckesson Corporation DBA SKY Packaginng
- 63739-008- Voriconazole
  - 63739-008-33- 3 BLISTER PACK in 1 BOX, UNIT-DOSE (63739-008-33) / 10 TABLET in 1 BLISTER PACK

64220- ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
- 64220-140-
  - 64220-140-00- 3 kg in 1 CANISTER (64220-140-00)

64220- ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
- 64220-140-
  64220-140-01- 5 kg in 1 CANISTER (64220-140-01)

64220- ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
- 64220-140-
  64220-140-02- 10 kg in 1 CANISTER (64220-140-02)

64220- ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
- 64220-140-
  64220-140-03- 15 kg in 1 CANISTER (64220-140-03)

64220- ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
- 64220-140-
  64220-140-04- 50 kg in 1 CANISTER (64220-140-04)

64220- ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
- 64220-140-
  64220-140-05- 10 kg in 1 DRUM (64220-140-05)

64220- ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
- 64220-140-
  64220-140-06- 15 kg in 1 DRUM (64220-140-06)

64220- ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
- 64220-140-
  64220-140-07- 20 kg in 1 DRUM (64220-140-07)

64220- ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
- 64220-140-
  64220-140-08- 25 kg in 1 DRUM (64220-140-08)

64220- ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
- 64220-140-
  64220-140-09- 50 kg in 1 DRUM (64220-140-09)

65015- MYLAN LABORATORIES LIMITED
- 65015-801-
  65015-801-61- 100 kg in 1 DRUM (65015-801-61)

65162- Amneal Pharmaceuticals LLC
- 65162-913- Voriconazole
  65162-913-22- 75 mL in 1 BOTTLE (65162-913-22)

65219- Fresenius Kabi USA, LLC
- 65219-190- Voriconazole
  - 65219-190-30- 1 VIAL, SINGLE-DOSE in 1 CARTON (65219-190-30) / 20 mL in 1 VIAL, SINGLE-DOSE

65372- Jubilant Pharmova Limited
- 65372-1175-
  - 65372-1175-2- 20 kg in 1 DRUM (65372-1175-2)

65841- Zydus Lifesciences Limited
- 65841-830- voriconazole
  65841-830-01- 100 TABLET in 1 BOTTLE (65841-830-01)

65841- Zydus Lifesciences Limited
- 65841-830- voriconazole
  - 65841-830-05- 500 TABLET in 1 BOTTLE (65841-830-05)

65841- Zydus Lifesciences Limited
- 65841-830- voriconazole
  - 65841-830-06- 30 TABLET in 1 BOTTLE (65841-830-06)

65841- Zydus Lifesciences Limited
- 65841-830- voriconazole
  - 65841-830-10- 1000 TABLET in 1 BOTTLE (65841-830-10)

65841- Zydus Lifesciences Limited
- 65841-830- voriconazole
  - 65841-830-16- 90 TABLET in 1 BOTTLE (65841-830-16)

65841- Zydus Lifesciences Limited
- 65841-830- voriconazole
  - 65841-830-77- 10 BLISTER PACK in 1 CARTON (65841-830-77) / 10 TABLET in 1 BLISTER PACK (65841-830-30)

65841- Zydus Lifesciences Limited
- 65841-831- voriconazole
  - 65841-831-01- 100 TABLET in 1 BOTTLE (65841-831-01)

65841- Zydus Lifesciences Limited
- 65841-831- voriconazole
  - 65841-831-05- 500 TABLET in 1 BOTTLE (65841-831-05)

65841- Zydus Lifesciences Limited
- 65841-831- voriconazole
  - 65841-831-06- 30 TABLET in 1 BOTTLE (65841-831-06)

65841- Zydus Lifesciences Limited
- 65841-831- voriconazole
  - 65841-831-10- 1000 TABLET in 1 BOTTLE (65841-831-10)

65841- Zydus Lifesciences Limited
- 65841-831- voriconazole
  - 65841-831-16- 90 TABLET in 1 BOTTLE (65841-831-16)

65841- Zydus Lifesciences Limited
- 65841-831- voriconazole
  - 65841-831-77- 10 BLISTER PACK in 1 CARTON (65841-831-77) / 10 TABLET in 1 BLISTER PACK (65841-831-30)

65862- Aurobindo Pharma Limited
- 65862-891- Voriconazole
  - 65862-891-01- 100 TABLET, FILM COATED in 1 BOTTLE (65862-891-01)

65862- Aurobindo Pharma Limited
- 65862-891- Voriconazole
  - 65862-891-03- 3 BLISTER PACK in 1 CARTON (65862-891-03) / 10 TABLET, FILM COATED in 1 BLISTER PACK (65862-891-10)

65862- Aurobindo Pharma Limited
- 65862-891- Voriconazole
  - 65862-891-05- 500 TABLET, FILM COATED in 1 BOTTLE (65862-891-05)

65862- Aurobindo Pharma Limited
- 65862-891- Voriconazole
  - 65862-891-30- 30 TABLET, FILM COATED in 1 BOTTLE (65862-891-30)

65862- Aurobindo Pharma Limited
- 65862-892- Voriconazole
  - 65862-892-01- 100 TABLET, FILM COATED in 1 BOTTLE (65862-892-01)

65862- Aurobindo Pharma Limited
- 65862-892- Voriconazole
  - 65862-892-03- 3 BLISTER PACK in 1 CARTON (65862-892-03) / 10 TABLET, FILM COATED in 1 BLISTER PACK (65862-892-10)

65862- Aurobindo Pharma Limited
- 65862-892- Voriconazole
  - 65862-892-05- 500 TABLET, FILM COATED in 1 BOTTLE (65862-892-05)

65862- Aurobindo Pharma Limited
- 65862-892- Voriconazole
  - 65862-892-30- 30 TABLET, FILM COATED in 1 BOTTLE (65862-892-30)

65862- Aurobindo Pharma Limited
- 65862-916-
  - 65862-916-37- 50 kg in 1 DRUM (65862-916-37)

66039- Glenmark Life Sciences Limited
- 66039-876-
  66039-876-04- 1 kg in 1 DRUM (66039-876-04)

66039- Glenmark Life Sciences Limited
- 66039-951-
  66039-951-04- 1 kg in 1 DRUM (66039-951-04)

68083- Gland Pharma Limited
- 68083-321- Voriconazole
  68083-321-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (68083-321-01) / 20 mL in 1 VIAL, SINGLE-DOSE

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-572- voriconazole
  - 68462-572-13- 3 BLISTER PACK in 1 CARTON (68462-572-13) / 10 TABLET, FILM COATED in 1 BLISTER PACK

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-572- voriconazole
  - 68462-572-30- 30 TABLET, FILM COATED in 1 BOTTLE (68462-572-30)

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-572- voriconazole
  - 68462-572-90- 90 TABLET, FILM COATED in 1 BOTTLE (68462-572-90)

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-573- voriconazole
  - 68462-573-13- 3 BLISTER PACK in 1 CARTON (68462-573-13) / 10 TABLET, FILM COATED in 1 BLISTER PACK

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-573- voriconazole
  - 68462-573-30- 30 TABLET, FILM COATED in 1 BOTTLE (68462-573-30)

68462- Glenmark Pharmaceuticals Inc., USA
- 68462-573- voriconazole
  - 68462-573-90- 90 TABLET, FILM COATED in 1 BOTTLE (68462-573-90)

68554- Hetero Labs Limited
- 68554-0111-
  - 68554-0111-1- 25 kg in 1 DRUM (68554-0111-1)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Classifications ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

Code ⬆